Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186186 · ClinicalTrials.gov registry record · Phase 4
Depakote ER in Bipolar Depression
A Phase 4 study of Depression, Bipolar, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT00186186 is a Phase 4 study of Depression, Bipolar that has completed, run by Stanford University. The registered enrollment target is 28 participants, below the 723-participant average among 5 other Depression, Bipolar trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00186186, a Phase 4 study of Depression, Bipolar, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.
Conditions Studied
Interventions
- DRUG Depakote ER
Study Locations (1)
California
- Stanford University Bipolar Disorders Clinic - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-01 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186186
The ClinicalTrials.gov registry entry for NCT00186186 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 723-participant average among 5 other Depression, Bipolar trials with a reported enrollment target (96% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression, Bipolar appearing as the primary indexed condition, and to 1 intervention - of which Depakote ER is the first listed.
NCT00186186 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00186186 about?
NCT00186186 is a clinical study titled "Depakote ER in Bipolar Depression". The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.
What is the current status of trial NCT00186186?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2004-01. Estimated completion is 2009-01.
What conditions does trial NCT00186186 study?
This clinical trial studies the following conditions: Depression, Bipolar.
What interventions are being tested in trial NCT00186186?
The interventions under investigation include: Depakote ER (DRUG).
Who is sponsoring clinical trial NCT00186186?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00186186 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression, Bipolar
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
RECRUITING · Phase 2
-
Dallas 2K: A Natural History Study of Depression
RECRUITING
-
Functional and Neurochemical Brain Changes Bipolar Depression
COMPLETED
-
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
COMPLETED · Phase 3
-
Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.